Market Scenario:                                                         

Over the last two hundred years, acid reflux has been a common lifestyle problem and also experienced a few setbacks in the U.S. Though, the ultimate goal of the gastroesophageal reflux treatment has always remained the same, which is to suppress the symptoms of the GERD patient. GERD affects up to 40% of the U.S. population in their lifetime and is a part of an increasingly significant public health burden. When GERD is not properly managed, it can lead to Barrett's esophagus. The lifetime risk of progression from GERD to Barrett's esophagus is 26.5%. Early diagnosis and treatment of Barrett's esophagus are crucial because it is the primary risk factor for esophageal cancer. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime. GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives but also extends to the healthcare system and economy.

Get Exclusive Sample Report @https://www.marketresearchfuture.com/sample_request/5554

Segmentation:                                                                                             

The Americas GERD & NERD treatment market is segmented on the basis of drug class, dosage form, and by the end user.

On the basis of the drug class, the market is segmented into antacids (acid neutralizers), proton pump inhibitors, H2 receptor blocker, prokinetic agents, antidepressants, calcium channel blockers, and others. Proton pump inhibitors are further segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. H2 receptor blocker is further segmented into ranitidine, famotidine, cimetidine, nizatidine, and others. Prokinetic agents are further segmented into domperidone, metoclopramide, itopride, prucalopride, cisapride, benzamide, mosapride, erythromycin, and others.

Intended Audience:                                                                                       

Medical Research Laboratories
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors
Key Findings:

Antacids segment dominates the market with nearly 26.11% share of the Americas GERD & NERD treatment market

Americas GERD & NERD treatment market was estimated to be USD 2,350.37 million in 2016

Proton pump inhibitors segment is expected to be the second largest market, which is expected to reach USD 773.62 million by 2023

Regional Analysis:

The American GERD & NERD treatment market is growing at a steady pace. North America contributed the largest share to the GERD & NERD treatment market owing to continuously increasing demand for the medical devices, increasing number of healthcare organization, and the presence of huge patient population. Increasing cases of smoking are projected to fuel in the Americas market. The South American region accounts the least share of the market.           

Key Players in the Americas GERD & NERD Treatment Market

Some of the major players in this market are: AstraZeneca Plc (U.K), Boston Scientific Corporation (U.S.), Cempra Inc. (U.S.), Eisai Co., Ltd. (Japan), EndoGastric Solutions Inc. (U.S.), EndoStim Inc. (U.S.), GlaxoSmithKline Plc (U.K), Ironwood Pharmaceuticals, Inc. (U.S.), Jeil pharmaceutical Co. Ltd. (South Korea), Johnson & Johnson (U.S.), Mederi Therapeutics Inc. (U.S.), Medigus Ltd. (Israel), Medtronic Inc. (U.S.), Merck & CO., Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceuticals Industries Limited (Israel), Torax Medical (U.S.), Valeant Pharmaceuticals International, Inc. (Canada), Carbon Medical technologies (U.S.), Allegiant health (U.S.), Tya pharmaceuticals (U.S.), and Sanofi (France).

Get Your Customized Report @https://www.marketresearchfuture.com/reports/gerd-and-nerd-treatment-market-5554

Table of Content:

1  REPORT PROLOGUE

2  MARKET INTRODUCTION

2.1 Definition 14

2.2 Scope Of The Study 14

2.2.1 Research Objective 14

2.2.2 Assumptions 14

2.2.3 Limitations 14

3  RESEARCH METHODOLOGY

3.1.1 Primary Research Methodology 17

3.1.2 Data Points Received From The Doctors/ Gastrologist: 17

3.1.3 Data Points Received From The Manufacturer/ Pharmaceutical Companies: 18

3.1.4 Data Points Received From Hospitals, Clinics: 18

3.1.5 Secondary Research Methodology 20

3.1.6 Market Share Analysis 22

3.1.7 Trade Analysis 22

3.1.8 Market Pricing Approach 22

TOC Continued…!

Get Discount @https://www.marketresearchfuture.com/check-discount/5554

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]